Announced a plan to allot new shares by third-party allotment to Maruishi Pharmaceutical Co., Ltd. and to allot stock acquisition rights to Macquarie Bank Limited for fundraising. The issue price will be determined using the 92% rule, with total fundraising expected to be approximately 2,205 million yen. Detailed terms including exercise period, conditions, non-exercise period, and lock-up for the stock acquisition rights were also disclosed.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-11","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261111-02.pdf","jir_short_summary":"Announced a plan to allot new shares by third-party allotment to Maruishi Pharmaceutical Co., Ltd. and to allot stock acquisition rights to Macquarie Bank Limited for fundraising. The issue price will be determined using the 92% rule, with total fundraising expected to be approximately 2,205 million yen. Detailed terms including exercise period, conditions, non-exercise period, and lock-up for the stock acquisition rights were also disclosed.","jir_summary":"### Overview of Fundraising\nKringle Pharma, Inc. announced fundraising by allotting new shares by third-party allotment to Maruishi Pharmaceutical Co., Ltd. and concurrently allotting stock acquisition rights to Macquarie Bank Limited. The issue price will be based on 92% of the share price, with a record date set to determine the final issue price. The total funds raised are expected to be approximately 2,205 million yen, to be used for U.S. clinical development preparation costs, establishment of active pharmaceutical ingredient (API) manufacturing capacity, domestic API manufacturing, and working capital.\n\n### Appropriateness and Impact of Allottees and Capital Policy\nThe allottees are Maruishi Pharmaceutical (which will hold a certain amount of the company's shares) and Xenoac HD (parent company of Nippon Zenyaku Kogyo), both intended to strengthen existing business relationships. Stock acquisition rights are allocated to Macquarie with a design to evaluate the exercise price on the record date and raise funds in stages. Dilution is estimated to be up to approximately 37%, and appropriateness has been confirmed through review by an independent committee.","jir_financial_highlights":"Amount of funds to be raised: 2,205 million yen (Unknown)\nTotal number of issued shares: 8,593,200 shares (Unknown)\nDilution rate: 37.15% (Unknown)","jir_category":"","jir_hashtags":"#KringlePharmaInc, #CapitalPolicy, #StockAcquisitionRights, #ThirdPartyAllotment","jir_key_figures":"Amount of funds to be raised: 2,205 million yen\nMaximum number of newly issued shares: 1,046,000 shares\nNumber of potential shares: 2,146,000 shares\nDilution rate: 37.15%\nNumber of shares allocated after allotment: Maruishi Pharmaceutical 627,600 shares \/ Xenoac HD 418,400 shares","jir_meta_title":"Kringle Pharma, Inc. Announces Terms for New Share Issuance\uff5cNovember 2026","jir_meta_description":"Kringle Pharma, Inc. announced a third-party allotment of new shares and issuance of stock acquisition rights. Issue price set by the 92% rule, total approximately 2,205 million yen; proceeds to be used for U.S. clinical trial preparation, manufacturing capacity build-out, and working capital.","jir_og_title":"Kringle Pharma, Inc. Announces Terms for New Share Issuance\uff5cNovember 2026","jir_og_description":"Disclosed allocation of new shares and stock acquisition rights, overview of use of proceeds, and estimated dilution. Assessed as having significant impact on shareholders and investors.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-149831","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n